Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN T ANDERSON

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1154543452
CMS profile
325086
Location
HOMEWOOD, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$138,963.90

269 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN T ANDERSON

NPI 1154543452 · CMS profile ID 325086

Allopathic & Osteopathic Physicians / Allergy & Immunology

HOMEWOOD, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154543452?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN T ANDERSON, NPI 1154543452, CMS profile ID 325086. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154543452?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN T ANDERSON, NPI 1154543452, CMS profile ID 325086. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154543452?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN T ANDERSON, NPI 1154543452, CMS profile ID 325086, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1154543452?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

269 matching records · $138,963.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 269 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 269.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharming Healthcare, Inc. $192.6608/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029323031 CMS
Amgen Inc. $12.8308/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019972003 CMS
GlaxoSmithKline, LLC. $13.0608/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001346595 CMS
GlaxoSmithKline, LLC. $3.5508/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001346701 CMS
GlaxoSmithKline, LLC. $0.8208/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001348457 CMS
Blueprint Medicines Corporation $14.9908/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256853 CMS
Blueprint Medicines Corporation $24.8908/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256859 CMS
Blueprint Medicines Corporation $29.9908/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256863 CMS
Blueprint Medicines Corporation $49.9908/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256871 CMS
Blueprint Medicines Corporation $14.9908/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051257083 CMS
Blueprint Medicines Corporation $75.7508/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256831 CMS
Blueprint Medicines Corporation $292.6708/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256879 CMS
Blueprint Medicines Corporation $35.0008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256867 CMS
Blueprint Medicines Corporation $504.8008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256883 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.9608/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055334085 CMS
Regeneron Healthcare Solutions, Inc. $19.0408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999077305 CMS
GlaxoSmithKline, LLC. $14.1208/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001346813 CMS
GlaxoSmithKline, LLC. $12.0308/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001346725 CMS
GENZYME CORPORATION $12.3908/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050299861 CMS
Genentech, Inc. $87.9108/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040406441 CMS
PFIZER INC. $19.1108/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050501497 CMS
AstraZeneca Pharmaceuticals LP $12.8108/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015293569 CMS
AstraZeneca Pharmaceuticals LP $17.8608/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011734303 CMS
GENZYME CORPORATION $17.8608/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050299881 CMS
LEO Pharma Inc. $6.3408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053450106 CMS
CSL Behring $34.5507/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891953 CMS
GlaxoSmithKline, LLC. $17.3607/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001348595 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.8507/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055334077 CMS
Takeda Pharmaceuticals U.S.A., Inc. $286.8507/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055334081 CMS
Pharming Healthcare, Inc. $32.0007/26/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029323007 CMS
Philips Electronics North America Corporation $15.2607/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024062967 CMS
kaleo, Inc. $18.6407/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013039055 CMS
GlaxoSmithKline, LLC. $16.7007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001348607 CMS
GlaxoSmithKline, LLC. $10.4507/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001346688 CMS
CSL Behring $93.7007/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042892293 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.2607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055334073 CMS
AstraZeneca Pharmaceuticals LP $20.7207/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014242885 CMS
CSL Behring $19.0007/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891947 CMS
GlaxoSmithKline, LLC. $15.6707/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001346622 CMS
CSL Behring $29.9007/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891937 CMS
Pharming Healthcare, Inc. $19.4506/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029322999 CMS
GENZYME CORPORATION $18.8906/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050299850 CMS
Blueprint Medicines Corporation $20.9006/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051256773 CMS
CSL Behring $799.2006/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891843 CMS
CSL Behring $35.2406/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891929 CMS
PFIZER INC. $17.6306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049213651 CMS
Takeda Pharmaceuticals U.S.A., Inc. $37.4006/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055334069 CMS
CSL Behring $453.9506/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891835 CMS
PFIZER INC. $19.2206/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050656485 CMS
CSL Behring $5,643.7506/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042891817 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94,987.67 216
PY2020 $84,967.50 173
PY2021 $100,540.64 200
PY2022 $88,627.38 232
PY2023 $138,963.90 269
PY2024 $161,432.55 298
PY2025 $119,863.43 225

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $199,900.93 33
PY2024 Principal investigator $235,679.95 308
PY2023 Recipient $491.16 2
PY2023 Principal investigator $462,493.70 246
PY2022 Principal investigator $197,993.95 105
PY2021 Principal investigator $826,228.55 218
PY2020 Principal investigator $198,372.30 67
PY2019 Principal investigator $436,271.73 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $2,258.40 12/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136476
Principal investigator 1 Novartis Pharmaceuticals Corporation $22.58 11/15/2025 Non-covered Recipient Entity
ALABAMA ALLERGY AND ASTHMA CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190308332
Principal investigator 1 CSL Behring $716.00 10/22/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673136
Principal investigator 1 SANOFI US SERVICES INC. $4,161.00 10/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136423
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,000.00 10/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA ALLERVIE CLINICAL RESEARCH
A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. No dispute reported 06/30/2026 1190309384
Principal investigator 1 SANOFI US SERVICES INC. $2,258.40 09/22/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136410
Principal investigator 1 SANOFI US SERVICES INC. $663.80 09/03/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136379
Principal investigator 1 SANOFI US SERVICES INC. $2,258.40 08/25/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136372
Principal investigator 1 SANOFI US SERVICES INC. $2,258.40 08/25/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136375
Principal investigator 1 CSL Behring $450.00 08/18/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673126
Principal investigator 1 CSL Behring $4,325.00 08/18/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673128
Principal investigator 1 SANOFI US SERVICES INC. $5,222.40 07/28/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136327
Principal investigator 1 CSL Behring $1,850.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673112
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 07/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136279
Principal investigator 1 SANOFI US SERVICES INC. $257.70 07/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136283
Principal investigator 1 SANOFI US SERVICES INC. $10,158.00 07/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136287
Principal investigator 1 CSL Behring $299.00 06/02/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673110
Principal investigator 1 CSL Behring $350.00 05/09/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673106
Principal investigator 1 CSL Behring $750.00 05/09/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673108
Principal investigator 1 CSL Behring $450.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673098
Principal investigator 1 Amgen Inc. $3,800.00 02/22/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH- COLUMBUS
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246638963
Principal investigator 1 SANOFI US SERVICES INC. $15,840.40 02/18/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama LLC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226136152
Principal investigator 1 CSL Behring $113.36 02/05/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673052
Principal investigator 1 CSL Behring $2,259.00 01/17/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673080
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,004.11 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190303279
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,122.34 01/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190303281
Principal investigator 1 CSL Behring $450.00 01/15/2025 Non-covered Recipient Entity
Clinical Research Center Of Alabama Homewood Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673076
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,792.90 01/15/2025 Non-covered Recipient Entity
ALABAMA ALLERGY AND ASTHMA CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190308334
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,473.04 01/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185552969
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,531.50 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190303277
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,879.25 01/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH CENTER OF ALABAMA
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190308708
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,871.40 01/01/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190310444
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,804.55 01/01/2025 Non-covered Recipient Entity
ALLERVIE CLINICAL RESEARCH
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190310448